Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The First Gene Therapy Provides a Durable Response for Non-Muscle-Invasive Bladder Cancer.

2.

The Effect of Common Steroids on Cancer Treatments.

3.

Study sheds light on challenges for women of color after breast cancer surgery

4.

In women with extremely dense breasts, elevated MRI enhancement can help identify cancer risk.

5.

Research discovery halts childhood brain tumor before it forms


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot